Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2011 2
2012 5
2013 3
2014 12
2015 15
2016 24
2017 19
2018 21
2019 12
2020 11
2021 7
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30527174

123 results

Results by year

Filters applied: . Clear all
Page 1
Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D, Yu F, Guo T, Zhou Y, Zhang J, Li Y, Jiang S, Mao J, Yang X, Chu L, Chu X, Wang S, Ni J, Zhu Z. Xu D, et al. Br J Radiol. 2022 Aug 1;95(1136):20220035. doi: 10.1259/bjr.20220035. Epub 2022 Jun 9. Br J Radiol. 2022. PMID: 35611637 Free PMC article.
Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, Camidge DR. Gan GN, et al. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):892-8. doi: 10.1016/j.ijrobp.2013.11.010. Epub 2014 Jan 22. Int J Radiat Oncol Biol Phys. 2014. PMID: 24462383 Free PMC article.
SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L, Kroeze SG, Guckenberger M. Basler L, et al. Lung Cancer. 2017 Apr;106:50-57. doi: 10.1016/j.lungcan.2017.02.007. Epub 2017 Feb 6. Lung Cancer. 2017. PMID: 28285694 Review.
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Bronte G, Franchina T, Alù M, Sortino G, Celesia C, Passiglia F, Savio G, Laudani A, Russo A, Picone A, Rizzo S, De Tursi M, Gambale E, Bazan V, Natoli C, Blasi L, Adamo V, Russo A. Bronte G, et al. Oncotarget. 2016 Jun 14;7(24):35803-35812. doi: 10.18632/oncotarget.8130. Oncotarget. 2016. PMID: 26993607 Free PMC article.
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N. Katayama R, et al. EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan. EBioMedicine. 2015. PMID: 26870817 Free PMC article.
123 results